A 52-year-old man with oat-cell carcinoma of the lung develops progressive proximal muscle weakness, depressed deep tendon reflexes, and autonomic dysfunction. A 48-year-old woman with ovarian cancer presents with progressive distal sensory loss, ataxia, and nystagmus with anti-Hu antibodies detected. Which laboratory/clinical finding best distinguishes Lambert-Eaton myasthenic syndrome (LEMS) from paraneoplastic cerebellar degeneration (PCD)?

Question

Accepted Answer

D. Electromyographic findings showing incremental response to high-frequency repetitive nerve stimulation. ## Discriminating LEMS from Paraneoplastic Cerebellar Degeneration

### Overview
LEMS and PCD are both paraneoplastic neurological syndromes, but they affect different anatomical sites (neuromuscular junction vs. cerebellum) and have distinct electrophysiological signatures.

### Pathophysiology

**Key Point:** LEMS is a disorder of the presynaptic neuromuscular junction (calcium channel dysfunction); PCD is a disorder of cerebellar Purkinje cells (antibody-mediated destruction).

### Comparison Table

| Feature | LEMS | PCD |
|---------|------|-----|
| **Primary site affected** | Neuromuscular junction (presynaptic) | Cerebellum (Purkinje cells) |
| **Clinical presentation** | Proximal weakness, hyporeflexia, autonomic dysfunction | Ataxia, nystagmus, dysarthria, cognitive decline |
| **EMG finding** | **Incremental response to high-frequency RNS** | Normal or non-specific changes |
| **Associated antibodies** | Anti-VGCC (P/Q-type, N-type) | Anti-Hu, Anti-Yo, Anti-CRMP5 |
| **Associated malignancy** | SCLC (80–90%) | SCLC, ovarian, breast, lymphoma |
| **Autonomic involvement** | Common (dry mouth, impotence, constipation) | Rare |
| **Response to 3,4-DAP** | Dramatic improvement | No response |

### High-Yield Electrophysiology

**High-Yield:** The **incremental response on high-frequency RNS** is PATHOGNOMONIC for LEMS and is the single most discriminating feature. In LEMS, repetitive stimulation at high frequency (20–50 Hz) causes progressive increase in compound muscle action potential (CMAP) amplitude by >100% — this is opposite to myasthenia gravis (decremental response).

**Mnemonic:** **LEMS = Incremental (goes UP with high-frequency stim)** because calcium channels are partially blocked; repeated stimulation opens more channels. **Myasthenia = Decremental (goes DOWN)** because acetylcholine receptors are blocked.

### Why EMG Discriminates

1. **LEMS:** Presynaptic calcium channel blockade → reduced acetylcholine release at rest → weak CMAP initially. High-frequency stimulation → calcium accumulation → increased ACh release → CMAP amplitude increases (incremental response).

2. **PCD:** Cerebellar degeneration does NOT affect neuromuscular transmission → EMG is normal or shows only non-specific myopathic changes. No incremental or decremental response.

### Clinical Pearl

**Clinical Pearl:** LEMS patients often improve dramatically with 3,4-diaminopyridine (3,4-DAP), which blocks potassium channels and prolongs action potentials, increasing calcium influx. PCD does not respond to 3,4-DAP because the problem is not at the neuromuscular junction.

[cite:Harrison 21e Ch 381; Robbins 10e Ch 7]

Answer

A. Association with small-cell lung cancer

Answer

B. Presence of anti-neuronal antibodies (anti-Hu, anti-Yo, anti-CRMP5)

Answer

C. Involvement of the cerebellum on MRI brain

Explanation

Discriminating LEMS from Paraneoplastic Cerebellar Degeneration

Overview

Pathophysiology

Comparison Table

High-Yield Electrophysiology

Why EMG Discriminates

Clinical Pearl

Practice similar questions

Join our NEET PG community

Feature	LEMS	PCD
Primary site affected	Neuromuscular junction (presynaptic)	Cerebellum (Purkinje cells)
Clinical presentation	Proximal weakness, hyporeflexia, autonomic dysfunction	Ataxia, nystagmus, dysarthria, cognitive decline
EMG finding	Incremental response to high-frequency RNS	Normal or non-specific changes
Associated antibodies	Anti-VGCC (P/Q-type, N-type)	Anti-Hu, Anti-Yo, Anti-CRMP5
Associated malignancy	SCLC (80–90%)	SCLC, ovarian, breast, lymphoma
Autonomic involvement	Common (dry mouth, impotence, constipation)	Rare
Response to 3,4-DAP	Dramatic improvement	No response